ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

ClinicalTrials.gov ID: NCT02363283

Public ClinicalTrials.gov record NCT02363283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma

Study identification

NCT ID
NCT02363283
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
37 participants

Conditions and interventions

Interventions

  • Glembatumumab Vedotin Drug
  • Laboratory Biomarker Analysis Other
  • Pharmacological Study Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 15, 2015
Primary completion
Jul 1, 2018
Completion
Jul 1, 2018
Last update posted
Aug 20, 2020

2015 – 2018

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Mayo Clinic Hospital Phoenix Arizona 85054
Mayo Clinic in Arizona Scottsdale Arizona 85259
University of Colorado Hospital Aurora Colorado 80045
Mayo Clinic in Florida Jacksonville Florida 32224-9980
Northwestern University Chicago Illinois 60611
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637
UC Comprehensive Cancer Center at Silver Cross New Lenox Illinois 60451
University of Chicago Medicine-Orland Park Orland Park Illinois 60462
University of Kansas Clinical Research Center Fairway Kansas 66205
University of Kansas Cancer Center Kansas City Kansas 66160
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114
Brigham and Women's Hospital Boston Massachusetts 02115
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Dana-Farber Cancer Institute Boston Massachusetts 02215
Mayo Clinic Rochester Minnesota 55905
Barnes-Jewish Hospital St Louis Missouri 63110
Washington University School of Medicine St Louis Missouri 63110
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756
Roswell Park Cancer Institute Buffalo New York 14263
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Penn State Milton S Hershey Medical Center Hershey Pennsylvania 17033-0850
University of Pennsylvania/Abramson Cancer Center Philadelphia Pennsylvania 19104
UT Southwestern/Simmons Cancer Center-Dallas Dallas Texas 75390
M D Anderson Cancer Center Houston Texas 77030
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02363283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 20, 2020 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02363283 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →